Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

A conjugate compound having the formula of A-(B)n,

• wherein:
• n is 1, 2, 3 or 4;
• A is a peptide compound;
• and
• B is a therapeutic agent, wherein B is connected to A, (i) at a free amine of said peptide compound, (ii) at an N-terminal position of said peptide compound, (iii) at a free-SH of said peptide compound, (iv) at a free carboxyl of said peptide compound, or (v) any combination of (i) to (iv);
• the peptide compound is a compound chosen from compounds of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX), formula (X), formula (XI), formula (XII) and formula (XIII), and if chosen from compounds of formulas (V) through (XIII) the peptide compound has at least 80% sequence identity to those compounds:
• X1X2X3X4X5GVX6AKAGVX7NX8FKSESY
• (SEQ ID NO:
• 1)
• (I)
• (X9)nGVX10AKAGVX11NX12FKSESY
• (SEQ ID NO:
• 2)
• (II)
• YKX13LRRX14APRWDX15PLRDPALRX16X17L
• (SEQ ID NO:
• 3)
• (III)
• YKX18LRR(X19)nPLRDPALRX20X21L
• (SEQ ID NO:
• 4)
• (IV)
• IKLSGGVQAKAGVINMDKSESM
• (SEQ ID NO:
• 5)
• (V)
• IKLSGGVQAKAGVINMFKSESY
• (SEQ ID NO:
• 6)
• (VI)
• IKLSGGVQAKAGVINMFKSESYK
• (SEQ ID NO:
• 7)
• (VII)
• GVQAKAGVINMFKSESY
• (SEQ ID NO:
• 8)
• (VIII)
• GVRAKAGVRNMFKSESY
• (SEQ ID NO:
• 9)
• (IX)
• GVRAKAGVRN(Nle)FKSESY
• (SEQ ID NO:
• 10)
• (X)
• YKSLRRKAPRWDAPLRDPALRQLL
• (SEQ ID NO:
• 11)
• (XI)
• YKSLRRKAPRWDAYLRDPALRQLL
• (SEQ ID NO:
• 12)
• (XII)
• YKSLRRKAPRWDAYLRDPALRPLL
• (SEQ ID NO:
• 13)
• (XIII)
• wherein
• X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X18 and X19 are independently chosen from any amino acid;
• X16, X17, X20 and X21 are independently chosen from Q, P, Y, I and L;
• m is 0, 1, 2, 3, 4 or 5;
• when X9 is present more than once, each of said X9 is independently chosen from any amino acid;
• when X19 is present more than once, each of said X19 is independently chosen from any amino acid;
• wherein a cysteine residue is added to said peptide compound at an N- and/or C-terminal end;
• wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end;
• and
• wherein B is connected to A via a linker.